Buquineran

This classification denotes a vasodilating agent and phosphodiesterase inhibitor with the molecular formula C20H29N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AWC1VMS3HC, chemically known as 1-butyl-3-(1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl)urea but generally known as buquineran, which bears US NIH Compound Identifier 71953. European Medicines Agency schedules Buquineran in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05986MIG. The term BUQUINERAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). BUQUINERAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule buquineran under HS 29335995 and SITC 51576. As of Q4 2014, BUQUINERAN remains the US FDA Preferred Term for this commodity. Buquineran bears US NLM identifiers UMLS ID C0107468 and NCI Concept Code C74355. SMILES: O=C(NC1CCN(CC1)c1ncnc2c1cc(OC)c(OC)c2)NCCCC.